ALB and chronic kidney disease: The EMPA-Kidney trial is unique in adding information to participants with CKD defined by an eGFR of at least 20 mL/min/1.73m2 but less than 45 mL/min/1.73m2 of body-surface area, or who had an eGFR of at least 45 mL/min/1.73m2 but less than 90 mL/min/1.73m2 with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200.